Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
08/11/2024 14:12
Nov 8 (Reuters) - Kineta Inc KANT.PK :
* KINETA UPDATES KVA12123 CLINICAL RESULTS FROM ONGOING
PHASE 1/2
VISTA101 STUDY AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (2024)
* KINETA INC - FAVORABLE TOLERABILITY AND TOXICITY PROFILE
IN BOTH
ARMS
Source text: ID:nGNX6NY3KD
Further company coverage: KANT.PK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Kineta
See all newsBrief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study